

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AGILA SPECIALTIES INC. AND
MYLAN PHARMACEUTICALS INC.,
Petitioners

v.

CUBIST PHARMACEUTICALS, INC.
Patent Owner

U.S. Patent No. 8,058,238

Case IPR2015: Unassigned

EXPERT DECLARATION OF CATHERINE MULLIGAN, PH.D

TABLE OF CONTENTS

I.	Qualifications and Background	1
A.	Education and Experience; Prior Testimony.....	1
B.	Bases for Opinions and Materials Considered	5
C.	Scope of Work	5
II.	Summary of Opinions.....	5
III.	Legal Standards	9
IV.	Person of Ordinary Skill in the Art.....	10
V.	The ‘238 Patent.....	12
VI.	Background.....	19
A.	Use of Surfactants and Biosurfactants	19
B.	Biosurfactant Purification and State of the Art in 2000.....	24
VII.	Scope and Content of the Prior Art References.....	34
A.	U.S. Patent No. 4,874,843 (‘843 Patent) [Ex.1007].....	34
B.	U.S. Patent No. 4,331,594 (‘594 Paten) [Ex.1009].....	35
C.	U.S. Patent No. 5,912,226 (“the ‘226 Patent”) [Ex.1010].....	36
D.	Baltz “Lipopeptide Antibiotics Produced by <i>Streptomyces roseosporus</i> and <i>Streptomyces fradiae</i> ,” in BIOTECHNOLOGY OF ANTIBIOTICS ed. W.R. Strohl (Marcel Dekker 1997) (“Baltz”) [Ex.1008].....	38
E.	Mulligan and Gibbs, “Recovery of Biosurfactants by Ultrafiltration,” <i>Journal of Chemical Technology & Biotechnology</i> ,	

	47:23-9 (1990) (“Mulligan”) [Ex. 1013].....	39
F.	Lin and Jiang, “Recovery and Purification of the Lipopeptide Biosurfactant <i>Bacillus subtilis</i> by Ultrafiltration,” <i>Biotechnology Techniques</i> , 11:413-6 (June 1997) (“Lin I”) [Ex. 1014].....	42
G.	Lin et al., “General Approach for the Development of High-Performance Liquid Chromatography Methods for Biosurfactant Analysis and Purification,” <i>Journal of Chromatography</i> , 825:149-59 (1998) (Lin II) [Ex. 1015]	44
H.	U.S. Patent No. 5,227,294 (‘294 Patent) [Ex. 1016].....	46
I.	Osman et al., “Tuning micelles of a bioactive heptapeptide biosurfactant via extrinsically induced conformational transition of surfactin assembly” <i>J. Peptide Sci.</i> , 4:449-458 (1998) (“Osman”) [Ex. 1017].....	47
J.	Tally et al., “Daptomycin: A Novel Agent for Gram-positive Infections,” <i>Expert Opin. Invest. Drugs</i> 8:1223-38 (1999) [Ex. 1018].....	49
VIII.	INVALIDITY OF THE ‘238 PATENT	50
A.	All Claims of the ‘238 Patent are Anticipated and/or Obvious Over the ‘226 Patent.....	50
B.	Claims 1 and 2 of the ‘238 Patent are Obvious Over the ‘843 Patent or ‘594 Patent In View Of Mulligan, Lin II, and/or the ‘226 Patent and the ‘294 Patent.....	90
C.	Claims 1-2 of the ‘238 Patent are Obvious Over the ‘594 Patent in View of Mulligan, Lin II, and/or the ‘226 Patent and the ‘294	

EXPERT DECLARATION OF CATHERINE N. MULLIGAN, PH.D.

Patent.....	97
D. Claims 3, 6, 7, 21-36, 49-51, 85-92, 105-107, 113-124, 144-146, 151-162, 164, 165, 175, 176, 183, 186-190 of the ‘238 Patent are Obvious Over the ‘843 Patent or the ‘594 Patent In View of Mulligan, Lin II and/or the ‘226 Patent	101
(a) Claims 3 and 6-7 of the ‘238 Patent Are Obvious	101
(b) Claims 21-36 of the ‘238 Patent are Obvious	106
(c) Independent Claims 49 and 50 and Dependent Claims 51, 85-92, 105-107, 113-124, 144-146, 151-162, 164, 165, 175 of the ‘238 Patent Are Invalid as Obvious Over the ‘843 Patent or ‘594 Patent in View of Mulligan, Lin II and/or the ‘226 Patent.....	111
(d) Claim 176 of the ‘238 Patent is Invalid as Obvious Over the ‘843 Patent or ‘594 Patent in View of Mulligan, Lin II and/or the ‘226 Patent	121
(e) Claims 183 and 186-190 of the ‘238 Patent are Invalid as Obvious Over the ‘843 Patent or ‘594 Patent in View of Mulligan, Lin II and/or the ‘226 Patent. 123	
E. Claims 4-5, 8-19, 93, 125-138, 166-167, 171, 173-174, 177-179 of the ‘238 Patent are Obvious Over the ‘843 Patent or ‘594 Patent In View of Mulligan, Lin I and/or Lin II and/or the ‘226 Patent	126
(a) Claims 4-5 of the ‘238 Patent are Invalid as Obvious	126
(b) Claims 8-9 of the ‘238 Patent is Invalid as Obvious Over the ‘843 Patent in View of Mulligan, Lin I, Lin II and/or the ‘226 Patent.....	130
(c) Claims 10-19 of the ‘238 Patent are Invalid as Obvious Over the ‘843 Patent or ‘594 Patent in View of Mulligan, Lin I, Lin II and/or the ‘226 Patent 133	

EXPERT DECLARATION OF CATHERINE N. MULLIGAN, PH.D.

(d)	Claims 93, 125-138, 166-167, 171, 173-174 and 177-179 of the ‘238 Patent are Invalid as Obvious Over the ‘843 Patent or the ‘594 Patent in View of Mulligan, Lin I, Lin II and/or the ‘226 Patent	138
F.	Claims 37-42, 48, 66-84, 94-99, 100-104, 112, 139-143, 163 and 182 of the ‘238 Patent are Obvious Over the ‘843 Patent In View of Mulligan, Lin II, and/or the ‘226 Patent and the ‘594 Patent.....	145
(a)	Claims 37-42 of the ‘238 Patent are Invalid as Obvious Over the ‘843 Patent in View of Mulligan, Lin II, and/or the ‘226 Patent, Lin I and the ‘594 Patent	146
(b)	Claims 48, 94-99, 100-104, 112, 139-143 and 163 of the ‘238 Patent are Invalid as Obvious Over the ‘843 Patent in View of Mulligan, Lin II and/or the ‘226 Patent and the ‘594 Patent	151
(c)	Claims 66-84 and 182 of the ‘238 Patent are Invalid as Obvious Over the ‘843 Patent In View of Mulligan, Lin II and/or the ‘226 Patent and Further In View of Baltz and the ‘594 Patent	160
G.	Claims 20, 43-47, 108-111, 147-150, 168-170, 172, 180-181, 184-185 and 191-192 of the ‘238 Patent are Obvious Over the ‘843 Patent or ‘594 Patent In View of Mulligan, Lin II and/or the ‘226 Patent and Further In View of Osman.....	170
(a)	Claim 20 of the ‘238 Patent is Invalid as Obvious Over the ‘843 Patent or the ‘594 Patent In View of Mulligan, Lin II and/or the ‘226 Patent and Further in View of Osman.....	170
(b)	Claims 43-47 of the ‘238 Patent are Invalid as Obvious Over the ‘843 Patent in View of Mulligan, Lin II and/or the ‘226 Patent and Further in View of Osman.....	173

EXPERT DECLARATION OF CATHERINE N. MULLIGAN, PH.D.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.